Jin Young-Hee, Lee Jihye, Jeon Sangeun, Kim Seungtaek, Min Jung Sun, Kwon Sunoh
KM Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea.
Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.
Biomedicines. 2022 May 18;10(5):1170. doi: 10.3390/biomedicines10051170.
The natural plant dietary polyphenols 1,2,3,4,6-O-Pentagalloylglucose (PGG) and proanthocyanidin (PAC) have potent antioxidant activity and a variety of pharmacological activities, including antiviral activity. In this study, we examined the inhibitory effect of PGG and PAC on SARS-CoV-2 virus infection, and elucidated its mode of action. PGG and PAC have dose-dependent inhibitory activity against SARS-CoV-2 infection in Vero cells. PGG has a lower IC (15.02 ± 0.75 μM) than PAC (25.90 ± 0.81 μM), suggesting that PGG has better inhibitory activity against SARS-CoV-2 than PAC. The PGG and PAC inhibit similar Mpro activities in a protease activity assay, with IC values of 25-26 μM. The effects of PGG and PAC on the activity of the other essential SARS-CoV-2 viral protein, RdRp, were analyzed using a cell-based activity assay system. The activity of RdRp is inhibited by PGG and PAC, and PGG has a lower IC (5.098 ± 1.089 μM) than PAC (21.022 ± 1.202 μM), which is consistent with their inhibitory capacity of SARS-CoV-2 infection. PGG and PAC also inhibit infection by SARS-CoV and MERS-CoV. These data indicate that PGG and PAC may be candidate broad-spectrum anticoronaviral therapeutic agents, simultaneously targeting the Mpro and RdRp proteins of SARS-CoV-2.
天然植物膳食多酚1,2,3,4,6 - 五没食子酰葡萄糖(PGG)和原花青素(PAC)具有强大的抗氧化活性和多种药理活性,包括抗病毒活性。在本研究中,我们检测了PGG和PAC对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒感染的抑制作用,并阐明了其作用模式。PGG和PAC对Vero细胞中的SARS-CoV-2感染具有剂量依赖性抑制活性。PGG的半数抑制浓度(IC)(15.02±0.75μM)低于PAC(25.90±0.81μM),表明PGG对SARS-CoV-2的抑制活性优于PAC。在蛋白酶活性测定中,PGG和PAC抑制类似的Mpro活性,IC值为25 - 26μM。使用基于细胞的活性测定系统分析了PGG和PAC对另一种重要的SARS-CoV-2病毒蛋白RNA依赖性RNA聚合酶(RdRp)活性的影响。RdRp的活性受到PGG和PAC的抑制,并且PGG的IC(5.098±1.089μM)低于PAC(21.022±1.202μM),这与其对SARS-CoV-2感染的抑制能力一致。PGG和PAC也抑制严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV)的感染。这些数据表明,PGG和PAC可能是同时靶向SARS-CoV-2的Mpro和RdRp蛋白的广谱抗冠状病毒治疗候选药物。